A calcium-channel blocker, benidipine improves forearm reactive hyperemia in patients with essential hypertension

Blood Pressure

Volumn 14, Issue SUPPL.1, 2005, Pages 39-44

  Makino, Hirofumi ^a   Aoki, Motokuni ^a   Hashiya, Naotaka ^a   Yamasaki, Keita ^a   Shimizu, Hideo ^a   Miwa, Ken ^a   Ogihara, Toshio ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Benidipine; Endothelial function; Forearm reactive hyperemia; HGF

Indexed keywords

BENIDIPINE; GLYCERYL TRINITRATE; SCATTER FACTOR; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; ENDOTHELIUM CELL; ENDOTHELIUM LESION; ESSENTIAL HYPERTENSION; FOREARM BLOOD FLOW; HUMAN; HYPEREMIA; MONOTHERAPY; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK FACTOR; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CYTOLOGY; DRUG EFFECT; FOREARM; HYPERTENSION; METABOLISM; MIDDLE AGED; PATHOLOGY; TIME; VASCULAR ENDOTHELIUM;

AGED; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; FOREARM; HEPATOCYTE GROWTH FACTOR; HUMANS; HYPEREMIA; HYPERTENSION; MIDDLE AGED; PLETHYSMOGRAPHY; REGIONAL BLOOD FLOW; REGRESSION ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; BLOOD FLOW VELOCITY; ENDOTHELIUM, VASCULAR; NITROGLYCERIN; VASODILATOR AGENTS;

EID: 22544435108     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08038020510040612     Document Type: Article

References (35)

1. Kato J, Aihara A, Kikuya M, Matsubara M, Ohta M, Ohkubo T, et al. Risk factors and predictors of coronary arterial lesions in Japanese hypertensive patients. Hypertens Res. 2001;24:3-11.
2. Glantz SA, Parmley WW. Passive smoking and heart disease. Epidemiology, physiology, and biochemistry. Circulation. 1991;83:1-12.
3. Zembowicz A, Hatchett RJ, Radziszewski W, Gryglewski RJ. Inhibition of endothelial nitric oxide synthase by ebselen. Prevention by thiols suggests the inactivation by ebselen of a critical thiol essential for the catalytic activity of nitric oxide synthase. J Pharmacol Exp Ther. 1993;267:1112-1118.
4. Benowitz NL. The role of nicotine in smoking-related cardiovascular disease. Prev Med. 1997;26:412-417.
5. Czernin J, Sun K, Brunken R, Bottcher M, Phelps M, Schelbert H. Effects of acute and long-term smoking on myocardial blood flow and flow reserve. Circulation. 1995;91:2891-2897.
6. Celermejer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993;88:2149-2155.
7. Barry J, Mead K, Nabel EG, Rocco MB, Campbell S, Fenton T, et al. Effect of smoking on the activity of ischemic heart disease. JAMA. 1989;261:398-402.
8. Raij L, DeMaster EG, Jaimes EA. Cigarette smoke-induced endothelium dysfunction: Role of superoxide anion. J Hypertens. 2001;19:891-897.
9. Mak IT, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. Circ Res. 1992;70:1099-1103.
10. Betz E, Hammerle H, Strohschneider T. Inhibition of smooth muscle cell proliferation and endothelial permeability with flunarizine in vitro and in experimental atheroma. Res Exp Med (Berl). 1985;185:325-340
11. Gunther J, Dhein S, Rosen R, Klaus W, Fricke U. Nitric oxide (EDRF) enhances the vasorelaxing effects of nitrendipine in various isolated arteries. Basic Res Cardiol. 1992;87:452-460.
12. Hayashi S, Morishita R, Higaki J, Aoki M, Moriguchi A, Kida I, et al. Autocrine-paracrine effects of overexpression of hepatocyte growth factor gene on growth of endothelial cells. Biochem Biophys Res Commun. 1996;220:539-545.
13. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A, et al. Hepatocyte growth factor is a novel member of the endothelium-specific growth factor: Additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertens. 1996;14:1067-1072.
14. Iwatsubo H, Nagano M, Sakai T, Kumamoto K, Morita R, Higaki J, et al. Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension. 1997;29:286-290.
15. Yamada A, Matsumoto K, Iwanari H, Sekiguchi K, Kawata S, Matsuzawa Y, et al. Rapid and sensitive enzyme-linked immunosorbent assay for measurement of HGF in rat and human tissues. Biomed Res. 1995;16:105-114.
16. Nakamura T. Structure and function of hepatocyte growth factor. Prog Growth Factor Res. 1991;3:67-86.
17. Boros P, Miller CM. Hepatocyte growth factor: A multi-functional cytokine. Lancet. 1995;345:293-295.
18. Tare M, Parkington HC, Coleman HA, Neild TO, Dusting GJ. Hyperpolarization and relaxation of atrial smooth muscle caused by nitric oxide derived from the endothelium. Nature. 1990;346:69-71.
19. Suga S, Nakao K, Itoh H, Komatsu Y, Ogawa Y, Hama N, et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-Β. Possible existence of "a vascular natriuretic peptide system". J Clin Invest. 1992; 90:1145-1149.
20. Dzau VJ. The role of mechanical and humoral factors in growth regulation of vascular smooth muscle cells and cardiac myocytes. Curr Opin Nephrol Hypertens. 1993;2:27-32.
21. Matsubara M, Hasegawa K. Effects of bedipine, a dihydropyridine-Ca2+ channel blocker, on expression of cytokine-induced adhesion molecules and chemoatrractants in human aortic endothelial cells. Eur J Pharmacol. 2004;498:303-314.
22. Aoki M, Nata T, Morishita R, Matsushita H, Nakagami H, Yamamoto K, et al. Endothelial apoptosis induced by oxidative stress through activation of NF-kappaB: Antiapoptotic effect of antioxidant agents on endothelial cells. Hypertension. 2001;38:48-55.
23. Matsushita H, Morishita R, Nata T, Aoki M, Nakagami H, Taniyama Y, et al. Hypoxia-induced endothelial apoptosis through nuclear factor-kappaB: (NF-kappaB)-mediated bcl-2 suppression: In vivo evidence of the importance of NF-kappaB in endothelial cell regulation. Circ Res. 2000;86:974-981.
24. Tsuda K, Nishio I. A calcium channel blocker, benidipine, improves cell membrance fluidity in human subjects via a nitric oxide-dependent mechanism An electron paramagnetic resonance investigation. Am J Hypertens. 2004;17:1143-1150.
25. Kobayashi N, Kobayashi K, Hara K, Higashi T, Yanaka H, Yagi S, et al. Benidipine stimulates nitric oxide synthase and improves coronary circulation in hypertensive rats. Am J Heypertens. 1999;12:483-491.
26. Asanuma H, Kitakaze M, Node K, Takashima S, Sakata Y, Asakura M, et al. Benidipine, a long-acting Ca channel blocker, limits infarct size via bradykinin-and NO-dependent mechanisms in canin hearts. Cardiovasc Drugs Ther. 2001;15:225-231.
27. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A, et al. Expression of local hepatocyte growth factor system in vascular tissues. Biochem Biophys Res Commun. 1995;215:483-488.
28. Nakano N, Moriguchi A, Morishita R, Higaki J, Yo Y, Yamada K, et al. Increased serum hepatocyte growth factor (HGF) and decreased local HGF in spontaneously hypertensive rats. (abstract) J Hypertens. 1996;14:S67.
29. Nakamura S, Moriguchi A, Morishita R, Aoki M, Yo Y, Hayashi S, et al. A novel vascular modulator, hepatocyte growth factor (HGF), as a potential index of the severity of hypertension. Biochem Biophys Res Commun. 1998;242:238-243.
30. Makino H, Aoki M, Hashiya N, Yamasaki K, Hiraoka K, Shimizu H, et al. Increase in peripheral blood flow by intravenous administration of protaglandin E1 in patients with peripheral arteral disease, accompanied by up-regulation of hepatocyte growth factor. Hypertens Res. 2004;27:85-91.
31. Hayashi S, Morishita R, Nakamura S, Yamamoto K, Moriguchi A, Nagano T, et al. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: Downregulation of HGF in response to hypoxia in vascular cells. Circulation. 199;100 Suppl II:II-301-II-308.
32. Morishita R, Nakamura S, Nakamura Y, Aoki M, Moriguchi A, Kida I, et al. Potential role of endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes mellitus, Diabetes. 1997;46:138-142.
33. Hayashi K, Nakamura S, Morishita R, Moriguchi A, Aoki M, Matsumoto K, et al. In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther. 2000;7:1664-1671.
34. Aoki M, Morishita R, Hayashi S, Jo N, Matsumoto K, Nakamura T, et al. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia. 2001;44: 1034-1042.
35. Yamasaki K, Aoki M, Makino H, Hashiya N, Shimizu H, Ohishi M, et al. Effect of nifedipine on endothelial function in normotensive smokers: Potential contribution of increase in circulating hepatocyte growth factor. J Hum Hypertens. 2004;18:701-705.